Management of severe pulmonary Langerhans cell histiocytosis in children.
Olive S EcksteinJed G NuchternGeorge B MalloryR Paul GuillermanMatthew A MusickMhairi BarclayJayesh M BhattPatrick DaviesRichard G GrundyAlice MartinTom HilliardStephen P LowisSusan PictonVasanta NanduriJohannes VisserCarl E AllenKenneth L McClainPublished in: Pediatric pulmonology (2020)
Patients with pulmonary Langerhans cell histiocytosis (LCH) typically have a benign course but may have extensive cystic lung disease with rare life-threatening complications including multiple and recurrent pneumothoraces and respiratory failure. We report seven severely affected pediatric patients treated with chemotherapy, aggressive chest tube management, and pleurodesis of whom five survived. Patients with extraordinary amounts of pulmonary cystic disease and multiple pneumothoraces due to LCH can have remarkable, curative outcomes with early recognition, optimal LCH-directed therapy, and supportive care.
Keyphrases
- pulmonary hypertension
- respiratory failure
- single cell
- cell therapy
- healthcare
- extracorporeal membrane oxygenation
- young adults
- stem cells
- mechanical ventilation
- squamous cell carcinoma
- early onset
- rectal cancer
- locally advanced
- pain management
- bone marrow
- insulin resistance
- adipose tissue
- chronic pain
- affordable care act
- childhood cancer